496 related articles for article (PubMed ID: 36071479)
1. The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy.
Shi C; Qin K; Lin A; Jiang A; Cheng Q; Liu Z; Zhang J; Luo P
J Exp Clin Cancer Res; 2022 Sep; 41(1):268. PubMed ID: 36071479
[TBL] [Abstract][Full Text] [Related]
2. The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers.
Zhu L; Liu J; Chen J; Zhou Q
J Hematol Oncol; 2021 Dec; 14(1):206. PubMed ID: 34930377
[TBL] [Abstract][Full Text] [Related]
3. The complementarity of DDR, nucleic acids and anti-tumour immunity.
Kornepati AVR; Rogers CM; Sung P; Curiel TJ
Nature; 2023 Jul; 619(7970):475-486. PubMed ID: 37468584
[TBL] [Abstract][Full Text] [Related]
4. Mutations in DNA damage response pathways as a potential biomarker for immune checkpoint blockade efficacy: evidence from a seven-cancer immunotherapy cohort.
Zhang W; Zhang L; Jiang H; Li Y; Wang S; Wang Q
Aging (Albany NY); 2021 Nov; 13(21):24136-24154. PubMed ID: 34747718
[TBL] [Abstract][Full Text] [Related]
5. Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy.
Huang JL; Chang YT; Hong ZY; Lin CS
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328658
[TBL] [Abstract][Full Text] [Related]
6. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
[TBL] [Abstract][Full Text] [Related]
7. Activation of the DDR Pathway Leads to the Down-Regulation of the TGFβ Pathway and a Better Response to ICIs in Patients With Metastatic Urothelial Carcinoma.
Zhou C; Lin A; Cao M; Ding W; Mou W; Guo N; Chen Z; Zhang J; Luo P
Front Immunol; 2021; 12():634741. PubMed ID: 34220801
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibitors in Tumors Harboring Homologous Recombination Deficiency: Challenges in Attaining Efficacy.
Silva SB; Wanderley CWS; Colli LM
Front Immunol; 2022; 13():826577. PubMed ID: 35211121
[TBL] [Abstract][Full Text] [Related]
9. Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control.
Concannon K; Morris BB; Gay CM; Byers LA
Mol Cell; 2023 Mar; 83(5):660-680. PubMed ID: 36669489
[TBL] [Abstract][Full Text] [Related]
10. Are DNA Repair Gene Alterations Associated With the Response to Platinum-Based Regimen and Immune Checkpoint Inhibitors in Patients With Solid Tumors?
Chabot C; Italiano A; Crombé A; Soubeyran I; Laizet Y; Khalifa E; Cousin S
Oncologist; 2024 May; 29(5):452-455. PubMed ID: 38558248
[TBL] [Abstract][Full Text] [Related]
11. DNA damage response-related immune activation signature predicts the response to immune checkpoint inhibitors: from gastrointestinal cancer analysis to pan-cancer validation.
Yan J; Wang S; Zhang J; Yuan Q; Gao X; Zhang N; Pan Y; Zhang H; Liu K; Yu J; Lu L; Liu H; Gao X; Zhao S; Zhang W; Reyila A; Qi Y; Zhang Q; Cang S; Lu Y; Pan Y; Kong Y; Nie Y
Cancer Biol Med; 2023 Dec; 21(3):252-66. PubMed ID: 38164720
[TBL] [Abstract][Full Text] [Related]
12. Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer.
Wang Y; Jiao X; Li S; Chen H; Wei X; Liu C; Gong J; Zhang X; Wang X; Peng Z; Qi C; Wang Z; Wang Y; Zhuo N; Zou J; Zhang H; Li J; Shen L; Lu Z
Cancer Biol Med; 2021 Sep; 19(8):1139-49. PubMed ID: 34570439
[TBL] [Abstract][Full Text] [Related]
13. Germline DNA damage response gene mutations as predictive biomarkers of immune checkpoint inhibitor efficacy.
Dennis MJ; Bylsma S; Madlensky L; Pagadala MS; Carter H; Patel SP
Front Immunol; 2024; 15():1322187. PubMed ID: 38348036
[TBL] [Abstract][Full Text] [Related]
14. Interfaces between cellular responses to DNA damage and cancer immunotherapy.
Pilger D; Seymour LW; Jackson SP
Genes Dev; 2021 May; 35(9-10):602-618. PubMed ID: 33888558
[TBL] [Abstract][Full Text] [Related]
15. Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer.
Ricciuti B; Recondo G; Spurr LF; Li YY; Lamberti G; Venkatraman D; Umeton R; Cherniack AD; Nishino M; Sholl LM; Shapiro GI; Awad MM; Cheng ML
Clin Cancer Res; 2020 Aug; 26(15):4135-4142. PubMed ID: 32332016
[TBL] [Abstract][Full Text] [Related]
16. Targeting DNA Damage Repair for Immune Checkpoint Inhibition: Mechanisms and Potential Clinical Applications.
Sun W; Zhang Q; Wang R; Li Y; Sun Y; Yang L
Front Oncol; 2021; 11():648687. PubMed ID: 34026622
[TBL] [Abstract][Full Text] [Related]
17. Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: rationale and clinical implication.
Lamberti G; Andrini E; Sisi M; Federico AD; Ricciuti B
Future Oncol; 2020 Aug; 16(23):1751-1766. PubMed ID: 32539551
[TBL] [Abstract][Full Text] [Related]
18. Radiation in Combination with Immune Checkpoint Blockade and DNA Damage Response Inhibitors in Mice: Dosage Optimization in MC38 Syngeneic Tumors via Modelling and Simulation.
Hodson D; Mistry H; Yates J; Farrington P; Staniszewska A; Guzzetti S; Davies M; Aarons L; Ogungbenro K
J Pharmacol Exp Ther; 2023 Oct; 387(1):44-54. PubMed ID: 37348964
[TBL] [Abstract][Full Text] [Related]
19. Triple kill: DDR inhibitors, radiotherapy and immunotherapy leave cancer cells with no escape.
Qiu Y; Hu X; Zeng X; Wang H
Acta Biochim Biophys Sin (Shanghai); 2022 Oct; 54(11):1569-1576. PubMed ID: 36305726
[TBL] [Abstract][Full Text] [Related]
20. Could Inhibiting the DNA Damage Repair Checkpoint Rescue Immune-Checkpoint-Inhibitor-Resistant Endometrial Cancer?
Li Y; Wang X; Hou X; Ma X
J Clin Med; 2023 Apr; 12(8):. PubMed ID: 37109350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
